UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY

REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 29, 2008

OR

TRANSITION REPORT

PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition

period from________to_______

COMMISSION FILE

NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235

East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip

code)

(212) 573-2323

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has

filed all reports required to be filed by Section 13 or 15(d) of the

Securities Exchange Act of 1934 during the preceding 12 months (or for such

shorter period that the registrant was required to file such reports) and (2)

has been subject to such filing requirements for the past 90 days.

YES X NO

Indicate by check mark whether the registrant is a large

accelerated filer, an accelerated filer, a non-accelerated filer or a smaller

reporting company. See definitions of "large accelerated filer," "accelerated

filer" and "smaller reporting company" in Rule 12b-2 of the

Exchange Act (Check one):

Large accelerated filer X Accelerated

filer Non-accelerated

filer Smaller

reporting company

Indicate by check mark whether the registrant is a shell

company (as defined in Rule 12b-2 of the Exchange Act).

YES NO X

At August 5, 2008, 6,740,994,347 shares of the issuer's

voting common stock were outstanding.

FORM 10-Q

For the Quarter

Ended

June 29, 2008

Table

of Contents

PART I. FINANCIAL

INFORMATION

Page

Item 1.

Financial Statements

Condensed

Consolidated Statements of Income for the three months and six months ended June

29, 2008, and July 1, 2007

Condensed Consolidated

Balance Sheets as of June 29, 2008, and December 31, 2007

Condensed

Consolidated Statements of Cash Flows for the six months ended June 29,

2008, and July 1, 2007

Notes to

Condensed Consolidated Financial Statements

Review Report

of Independent Registered Public Accounting Firm

16

Item 2.

Management's

Discussion and Analysis of Financial Condition and Results of Operations

17

Item 3.

Quantitative

and Qualitative Disclosures About Market Risk

44

Item 4.

Controls and

Procedures

44

PART II. OTHER

INFORMATION

Item 1.

Legal

Proceedings

45

Item 1A.

Risk Factors

47

Item 2.

Unregistered

Sales of Equity Securities and Use of Proceeds

48

Item 3.

Defaults Upon Senior

Securities

48

Item 4.

Submission of

Matters to a Vote of Security Holders

48

Item 5.

Other

Information

48

Item 6.

Exhibits

49

Signature

50

PART

I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three

Months Ended

Six

Months Ended

(millions,

except per common share data)

June 29,

2008

July

1, 2007

June 29,

2008

July

1, 2007

Revenues

12,129

11,084

23,977

23,558

Costs and expenses:

Cost of sales(a)

2,289

2,109

4,275

3,996

Selling,

informational and administrative expenses(a)

3,863

3,844

7,355

7,205

Research and

development expenses(a)

1,966

2,165

3,757

3,830

Amortization of

intangible assets

663

783

1,442

1,598

Acquisition-related

in-process research and development charges

156

--

554

283

Restructuring

charges and acquisition-related costs

569

1,051

747

1,863

Other

(income)/deductions - net

(167)

(487)

(500)

(889)

Income from

continuing operations before provision for taxes on income and minority

interests

2,790

1,619

6,347

5,672

Provision for

taxes on income

25

272

788

961

Minority

interests

12

Income from

continuing operations

2,759

1,345

5,547

4,706

Discontinued

operations:

Loss from

discontinued operations - net of tax

(1)

--

(5)

--

Gains/(losses) on

sales of discontinued operations - net of tax

18

(78)

18

(47)

Discontinued

operations - net of tax

17

(78)

13

(47)

Net income

2,776

1,267

5,560

4,659

Earnings per common share - basic:

Income from

continuing operations

0.41

0.19

0.82

0.67

Discontinued

operations - net of tax

--

(0.01)

0.01

(0.01)

Net income

0.41

0.18

0.83

0.66

Earnings per common share -

diluted:

Income from

continuing operations

0.41

0.19

0.82

0.67

Discontinued

operations - net of tax

--

(0.01)

--

(0.01)

Net income

0.41

0.18

0.82

0.66

Weighted-average

shares used to calculate earnings per common share:

Basic

6,732

6,966

6,736

7,009

Diluted

6,748

6,990

6,754

7,033

Cash dividends paid per common

share

0.32

0.29

0.64

0.58

(a)

Exclusive of amortization of

intangible assets, except as disclosed in Note 9B. Goodwill and Other

Intangible Assets: Other Intangible Assets.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(millions

of dollars)

June 29,

2008*

Dec. 31,

2007**

ASSETS

Cash and cash equivalents

820

3,406

Short-term investments

25,359

22,069

Accounts receivable, less allowance

for doubtful accounts

10,245

9,843

Short-term loans

1,041

617

Inventories

5,334

5,302

Taxes and other current assets

5,711

5,498

Assets held for sale

141

114

Total current assets

48,651

46,849

Long-term

investments and loans

7,105

4,856

Property, plant and equipment, less

accumulated depreciation

14,925

15,734

Goodwill

21,704

21,382

Identifiable

intangible assets, less accumulated amortization

19,875

20,498

Other assets,

deferred taxes and deferred charges

4,255

5,949

Total assets

116,515

115,268

LIABILITIES

AND SHAREHOLDERS' EQUITY

Short-term borrowings, including

current portion of long-term debt

9,448

5,825

Accounts payable

1,928

2,270

Dividends payable

2,147

2,163

Income taxes payable

930

1,380

Accrued compensation and related

items

1,640

1,974

Other current liabilities

7,100

8,223

Total current liabilities

23,193

21,835

Long-term debt

7,246

7,314

Pension benefit

obligations

2,487

2,599

Postretirement

benefit obligations

1,746

1,708

Deferred taxes

5,885

7,696

Other taxes

payable

6,605

6,246

Other

noncurrent liabilities

2,635

2,746

Total liabilities

49,797

50,144

Minority interests

149

114

Preferred stock

81

93

Common stock

443

442

Additional

paid-in capital

69,996

69,913

Employee

benefit trust, at fair value

(399)

(550)

Treasury stock

(57,385)

(56,847)

Retained

earnings

50,912

49,660

Accumulated

other comprehensive income

2,921

2,299

Total shareholders' equity

66,569

65,010

Total liabilities and shareholders'

equity

116,515

115,268

* Unaudited.

** Condensed from audited

financial statements.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Six Months

Ended

(millions

of dollars)

June 29,

2008

July 1,

2007

Operating

Activities:

Net income

5,560

4,659

Adjustments to

reconcile net income to net cash provided by operating activities:

Depreciation

and amortization

2,716

2,712

Share-based

compensation expense

166

228

Acquisition-related

in-process research and development charges

554

283

Deferred taxes

from continuing operations

439

(951)

Other non-cash

adjustments

509

(4)

Changes in

assets and liabilities (net of businesses acquired and divested)

(1,631)

(2,019)

Net cash provided by operating

activities

8,313

4,908

Investing Activities:

Purchases of

property, plant and equipment

(868)

(757)

Purchases of

short-term investments

(16,106)

(10,738)

Proceeds from sales

and redemptions of short-term investments

12,463

17,101

Purchases of

long-term investments

(3,856)

(1,243)

Proceeds from sales

and redemptions of long-term investments

632

22

Purchases of

other assets

(32)

(82)

Acquisitions,

net of cash acquired

(962)

(463)

Other investing

activities

(219)

(293)

Net cash (used in)/provided by

investing activities

(8,948)

3,547

Financing Activities:

Increase in

short-term borrowings, net

16,310

78

Principal

payments on short-term borrowings

(14,097)

(763)

Proceeds from

issuances of long-term debt

602

1,243

Principal

payments on long-term debt

--

(60)

Purchases of

common stock

(500)

(4,999)

Cash dividends

paid

(4,277)

(4,040)

Stock option

transactions and other

33

383

Net cash used

in financing activities

(1,929)

(8,158)

Effect of

exchange-rate changes on cash and cash equivalents

(22)

14

Net (decrease)/increase

in cash and cash equivalents

(2,586)

311

Cash and cash

equivalents at beginning of period

3,406

1,827

Cash and cash

equivalents at end of period

820

2,138

Supplemental

Cash Flow Information:

Cash paid

during the period for:

Income taxes

1,056

3,672

Interest

446

354

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of

Presentation

We prepared the condensed

consolidated financial statements following the requirements of the Securities

and Exchange Commission (SEC) for interim reporting. As permitted under those

rules, certain footnotes or other financial information that are normally

required by accounting principles generally accepted in the United States of

America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and

operating results for subsidiaries operating outside the U.S. are as of and for

the three-month and six-month periods ended May 25, 2008, and May 27, 2007.

Revenues, expenses, assets and

liabilities can vary during each quarter of the year. Therefore, the results

and trends in these interim financial statements may not be representative of

those for the full year.

We are responsible for the unaudited

financial statements included in this document. The financial statements

include all normal and recurring adjustments that are considered necessary for

the fair presentation of our financial position and operating results.

The information included in this

Quarterly Report on Form 10-Q should be read in conjunction with the

consolidated financial statements and accompanying notes included in Pfizer's

Annual Report on Form 10-K for the year ended December 31, 2007.

Note 2. Adoption of New

Accounting Policies

As of January 1, 2008, we adopted on

a prospective basis certain required provisions of Statement of Financial

Accounting Standards (SFAS) No. 157, Fair Value Measurements, as amended

by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157-2,

Effective Date of FASB Statement No. 157. Those provisions relate to our

financial assets and liabilities carried at fair value and our fair value

disclosures related to financial assets and liabilities. SFAS 157 defines fair

value, expands related disclosure requirements and specifies a hierarchy of

valuation techniques based on the nature of the inputs used to develop the fair

value measures. Fair value is defined as the price that would be received to

sell an asset or paid to transfer a liability in an orderly transaction between

market participants at the measurement date. There are three levels of inputs

to fair value measurements - Level 1, meaning the use of quoted prices for

identical instruments in active markets; Level 2, meaning the use of quoted

prices for similar instruments in active markets or quoted prices for identical

or similar instruments in markets that are not active or are directly or

indirectly observable; and Level 3, meaning the use of unobservable inputs.

Observable market data should be used when available.

Many, but not all, of our financial

instruments are carried at fair value. For example,

substantially all of our cash equivalents, short-term investments and long-term

investments are classified as available-for-sale securities and are carried at

fair value, with unrealized gains and losses, net of tax, reported in Other

comprehensive income. Derivative financial instruments are carried

at fair value, with changes in fair value reported in various balance sheet

categories (see both Note 10 D. Financial Instruments: Derivative Financial

Instruments and Hedging Activities in our Annual Report on Form 10-K for the

year ended December 31, 2007, and Note 7C. Financial Instruments: Derivative

Financial Instruments and Hedging Activities in this Quarterly Report) and

ultimately, in Other (income)/deductions - net. Virtually all of our

valuation measurements are Level 2 measurements. The adoption of SFAS 157 did

not have a significant impact on our consolidated financial statements. We did

not elect to adopt SFAS 157 for acquired nonfinancial assets and assumed nonfinancial

liabilities.

Emerging Issues Task Force (EITF)

Issue No. 07-3, Accounting for Nonrefundable Advance Payments for Goods or

Services to Be Used in Future Research and Development Activities, became

effective for new contracts entered into on or after January 1, 2008. EITF

Issue No. 07-3 requires that non-refundable advance payments for goods and

services that will be used in future research and development (R&D)

activities be expensed when the R&D activity has been performed or

when the R&D goods have been received rather than when the payment is made.

The adoption of EITF Issue No. 07-3 did not have a significant impact on our consolidated

financial statements.

Note 3. Acquisitions

During the first six months of 2008

and 2007, we acquired the following:

In the second quarter of 2008, we

acquired Encysive Pharmaceuticals Inc. (Encysive), a biopharmaceutical

company, whose main product (Thelin), for the treatment of pulmonary arterial

hypertension, is commercially available in much of the E.U., is approved in

certain other markets, and is under review by the Food and Drug

Administration (FDA). The cost of acquiring Encysive, through a tender offer

and subsequent merger, was approximately $200 million, including

transaction costs. Upon our acquisition of Encysive, Encysive's change of

control repurchase obligations under its $130 million 2.5% convertible

notes came into effect and, as such, Encysive repurchased the convertible

notes in consideration for their par value plus accrued interest in June 2008.

In addition, in the second quarter of 2008, we acquired Serenex, Inc.

(Serenex), a privately held biotechnology company with SNX-5422, an oral Heat

Shock Protein 90 (Hsp90) inhibitor currently in Phase I trials for the

potential treatment of solid tumors and hematological malignancies and an

extensive Hsp90 inhibitor compound library, which has potential uses in

treating cancer, inflammatory and neurodegenerative diseases. In connection

with these acquisitions, we recorded $156 million in Acquisition-related

in-process research and development charges and approximately $450

million in intangible assets.

In the first quarter of 2008, we

acquired CovX, a privately held biotherapeutics company specializing in

preclinical oncology and metabolic research and the developer of a

biotherapeutics technology platform that we expect will enhance our biologic

portfolio. Also in the first quarter of 2008, we acquired all the outstanding

shares of Coley Pharmaceutical Group, Inc., (Coley), a biopharmaceutical

company specializing in vaccines and drug candidates designed to fight

cancers, allergy and asthma disorders, and autoimmune diseases, for

approximately $230 million. In connection with these and two smaller

acquisitions related to Animal Health, we recorded $398 million in Acquisition-related

in-process research and development charges.

In the first quarter of 2007, we

acquired BioRexis Pharmaceutical Corp., a privately held biopharmaceutical

company with a number of diabetes candidates and a novel technology platform

for developing new protein drug candidates, and Embrex, Inc., an animal

health company that possesses a unique vaccine delivery system known as

Inovoject that improves consistency and reliability by inoculating chicks

while they are still inside the egg. In connection with these and other small

acquisitions, we recorded $283 million in Acquisition-related

in-process research and development charges.

Note 4. Cost-Reduction

Initiatives

The costs incurred in connection with

our cost-reduction initiatives follow:

Three

Months Ended

Six

Months Ended

(millions

of dollars)

June

29,

2008

July 1,

2007

June

29,

2008

July 1,

2007

Implementation

costs(a)

405

317

762

491

Restructuring

charges(b)

562

1,035

739

1,830

Total costs

related to our cost-reduction initiatives

967

1,352

1,501

2,321

(a)

For

the second quarter of 2008, included in Cost of sales ($210 million),

Selling, informational and administrative expenses ($100 million), Research

and development expenses ($94 million), and Other (income)/deductions

- net ($1 million). For the second quarter of 2007, included

in Cost of sales ($170 million), Selling, informational and

administrative expenses ($79 million), Research and development

expenses ($131 million) and Other (income)/deductions -

net

($63 million income). For the first six months of 2008, included in Cost

of sales ($348 million), Selling, informational and

administrative expenses ($175 million), Research and development

expenses ($240 million), and Other (income)/deductions - net

($1 million income). For the first six months of 2007, included in Cost

of sales ($264 million), Selling, informational and

administrative expenses ($128 million), Research and development

expenses ($162 million) and Other (income)/deduction -

net

($63 million income).

(b)

Included

in Restructuring charges and acquisition-related costs.

Through June 29, 2008, the

restructuring charges primarily relate to our plant network optimization

efforts and the restructuring of our U.S. marketing and worldwide research and

development operations, while the implementation costs primarily relate to accelerated

depreciation of certain assets, as well as system and process standardization

and the expansion of shared services.

The components of restructuring charges

associated with our cost-reduction initiatives follow:

(millions

of dollars)

Costs

Incurred

Through

June 29,

2008

Activity

Through

June 29,

2008

(a)

Accrual

as of

June 29,

2008

(b)

Employee

termination costs

3,391

2,395

996

Asset

impairments

1,215

1,215

--

Other

390

294

96

Total